Fig. 1: The value of the first sBCMA sample is shown in patients who progress to active MM during follow up, compared to those patients who do not progress.
From: Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
A Demonstrates that in MGUS patients, the median baseline sBCMA in patients that did not progress to MM during follow up was 43.7 (IQR 25.0–82.3) ng/mL, compared to 106.5 (IQR 78.9–227.3) ng/mL in patients that did progress to MM. B Demonstrates that in SMM patients, the median baseline sBCMA in patients that did not progress to MM during follow up was 101.7 (IQR 67.4–165.5) ng/mL, compared to 162.7 (IQR 90.5–275.8) ng/mL in patients that did progress to MM.
